CRISPR-Cas9

[npj Precision Oncology] Using genetic as well as pharmacological tools, researchers showed that targeting the MEK5/ERK5 route was therapeutically effective in lung cancer.

[ERS Genomics Limited] ERS Genomics Limited announced a non-exclusive license agreement granting CET access to ERS Genomics’ CRISPR/Cas9 patent portfolio.

[Nature Communications] In primary hematopoietic progenitor/stem cells, researchers detected 1.1% of clones with acquired megabase losses of heterozygosity induced by CRISPR-Cas9.

[eLife] Scientists established two murine Ebf1-deficient pro-B cell lines, with and without T-lineage potential. The latter expressed lower levels of Lmo2; their potential was restored via ectopic expression of Lmo2.

[Stem Cell Research] Investigators reprogrammed skin fibroblasts from a hypertrophic cardiomyopathy patient carrying a heterozygous MYBPC3 truncating mutation into human iPSC (hiPSC) and used CRISPR/Cas9 to generate bi-allelic MYBPC3 truncating mutation and isogenic control hiPSC lines.

[Cellular & Molecular Immunology] The authors generated PD-1 and T cell receptor deficient mesothelin-specific CAR-T cells using CRISPR-Cas9 technology and evaluated them in a dose-escalation study.